Кардиоваскулярная терапия и профилактика (Jan 1970)
Antihypertensive spirapril effectiveness in patients with mild to moderate arterial hypertension
Abstract
Aim. То study 12-week spirapril (Quadropril®) therapy effectiveness in patients with mild to moderate arterial hypertension (АП). Material and metliods. For 12 weeks, 62 patients with mild to moderate АП received spirapril (6 mg/d), with diuretics (hydrochlorthiazide or Arifon retard) added if antihypertensive effect was insufficient. Results. Blood pressure (BP) normalized in 25,8% of the patients. Adding diuretics (hydrochlorthiazide, 25 mg/d, or Arifon® retard, 1,5 mg/d) normalized BP in the rest of the participants. Circadian BP rhythm was also normalized. Spirapril was well tolerated by the patients. Conclusion. ACE inhibitor spirapril (Quadropril®) effectively normalizes BP in patients with mild to moderate АП. In case of insufficient antihypertensive effect, combination with diuretics allows to normalize BP in extra 87% of the patients.